Hepatitis C Therapy: Other Players in the Game

Joseph Ahn, Steven L. Flamm

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Therapies in addition to the direct-acting antiviral agents (DAA) under evaluation for chronic hepatitis C include host targets such as cyclophilin inhibitors and immunomodulators. Both passive and therapeutic vaccines hold promise for the future. Although the numbers of drug categories and individual agents are increasing, only a handful of the non-DAAs seem to be ready to move on to phase III trials. New interferon agents are in development, and ribavirin variants are still under consideration. The role of the other players in the overall armamentarium against hepatitis C virus is still evolving.

Original languageEnglish (US)
Pages (from-to)641-656
Number of pages16
JournalClinics in liver disease
Issue number3
StatePublished - Aug 2011
Externally publishedYes


  • Cyclophilin inhibitor
  • Hepatitis C
  • TLR agonist
  • Therapeutic vaccine
  • Thiazolide

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Hepatitis C Therapy: Other Players in the Game'. Together they form a unique fingerprint.

Cite this